Related Experiment Video

Updated: Jul 1, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

409

C3 Glomerulopathy: Novel Treatment Paradigms

Blanca Tarragon Estebanez1, Andrew S Bomback1

  • 1Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.

Kidney International Reports
|March 14, 2024
PubMed

Insights

C3 glomerulopathy (C3G) is a kidney disease driven by the alternative complement pathway. New therapies targeting this pathway show promise for treating C3G, unlike older, less effective treatments.

Area of Science:

  • Nephrology
  • Immunology
  • Complement System Biology

Background:

  • C3 glomerulopathy (C3G) is characterized by isolated or dominant C3 deposition in glomeruli.
  • The alternative complement pathway hyperactivity is the primary cause of glomerular injury in C3G.
  • Current treatment paradigms for C3G are evolving due to novel therapeutic developments.

Purpose of the Study:

  • To review the evolution of treatment strategies for C3 glomerulopathy.
  • To assess the efficacy of non-complement targeting therapies.
  • To highlight advancements in complement cascade-targeting agents for C3G.

Main Methods:

  • Review of existing literature on C3 glomerulopathy treatments.
  • Analysis of clinical trial data for complement-targeting agents.
  • Evaluation of pathogenetic mechanisms in C3G.

Main Results:

  • Non-complement targeting therapies demonstrate limited efficacy in C3G.
  • Emerging complement-targeting agents are under investigation.
  • Disease-specific therapies are being developed to address the complement cascade.

Conclusions:

  • Targeting the complement cascade offers a promising therapeutic avenue for C3G.
  • Future treatments for C3G will likely focus on complement pathway modulation.
  • Understanding the pathogenesis is key to developing effective C3G therapies.

Keywords:
complementglomerulonephritis

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.4K
Isolation of Glomeruli and In Vivo Labeling of Glomerular Cell Surface Proteins09:12

Isolation of Glomeruli and In Vivo Labeling of Glomerular Cell Surface Proteins

Published on: January 18, 2019

9.1K

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
444
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
488
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186